

MASTER'S THESIS

A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of MicroRans in osteoclasts

Dang, Lei

Date of Award:
2016

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

Abstract

Dysregulated microRNAs in osteoclasts could cause many skeletal diseases. The therapeutic manipulation of these pathogenic microRNAs necessitates novel, efficient delivery systems to facilitate microRNAs modulators targeting osteoclasts with minimal off-target effects. Bone resorption surfaces characterized by highly crystallized hydroxyapatite are dominantly occupied by osteoclasts. Considering that the eight repeating sequences of aspartate (D-Asp₈) could preferably bind to highly crystallized hydroxyapatite, we developed a targeting system by conjugating D-Asp₈ peptide with liposome for delivering microRNA modulators specifically to bone resorption surfaces and subsequently encapsulated antagomir-148a (a microRNA modulator suppressing the osteoclastogenic miR-148a), *i.e.* (D-Asp₈)-liposome-antagomir-148a. Our results demonstrated that D-Asp₈ could facilitate the enrichment of antagomir-148a and the subsequent down-regulation of miR-148a in osteoclasts *in vivo*, resulting in reduced bone resorption and attenuated deterioration of trabecular architecture in osteoporotic mice. Mechanistically, the osteoclast-targeting delivery depended on the interaction between bone resorption surfaces and D-Asp₈. No detectable liver and kidney toxicity was found in mice after single/multiple dose(s) treatment of (D-Asp₈)-liposome-antagomir-148a. These results indicated that (D-Asp₈)-liposome as a promising osteoclast-targeting delivery system could facilitate clinical translation of microRNA modulators in treating those osteoclast-dysfunction-induced skeletal diseases.

Table of Contents

Abstract	iii
Acknowledge	V
Table of Contents.....	Vi
List of Figures.....	Viii
List of Tables.....	IX
List of abbreviation	X
Chapter One Introduction	1
1. Challenges associated with skeletal disorders	1
2. MicroRNA modulators as one of therapeutic strategies.....	1
3. Challenges for <i>in vivo</i> delivery of microRNA modulators	2
4. Targeted-drug delivery as one of therapeutic approaches.....	3
4.1 Targeting moieties	4
4.1.1 Bone tissue-targeting moieties	5
4.1.2 Cell-specific targeting moieties.....	10
4.1.3 Potential targeting moieties.....	14
4.2 Nanoparticles	16
4.2.1 Lipid nanoparticles	16
4.2.2 Poly(lactic-co-glycolic acid) nanoparticles.....	19
5. Strategies of microRNA modulators delivery to osteoclasts for inhibiting bone resorption.....	20
6. Objective of present study	21
Chapter Two Experimental design and results	22
1. Introduction.....	22
2. Materials and methods	24
2.1 Materials.....	24
2.2 Animal handling.....	25
2.3 Preparation of (D-Asp ₈)-liposome-antagomir-148a	25
2.3.1 Experimental Design	25
2.3.2 HPLC analysis for conjugation of D-Asp ₈ moiety to liposome surfaces	26
2.4 Characterization of (D-Asp ₈)-liposome-antagomir-148a	27
2.4.1 Experimental Design	27
2.5 Tissue-selective delivery analysis of antagomir-148a <i>in vivo</i>	27
2.5.1 Experimental design.....	27
2.5.2 Biophotonic Imaging Analysis.....	28
2.5.3 Microplate Reader Analysis.....	28
2.6 Cell-selective delivery examination of antagomir-148a <i>in vivo</i> ..	29
2.6.1 Experimental Design	29
2.6.2 Immunohistochemistry	30
2.7 The dose-response pattern and persistence of miR-148a	

knockdown <i>in vivo</i>	31
2.7.1 Experimental Design	31
2.7.2 Total RNA extraction, reverse transcription and quantitative real-time PCR.....	32
2.8 Cell-specific knockdown efficiency assay of miR-148a <i>in vivo</i> ..	32
2.8.1 Experimental Design	32
2.8.2 Fluorescence-activated cell sorting	33
2.9 Examination of liver and kidney toxicity after single and multiple dose(s)	34
2.9.1 Experimental Design	34
2.9.2 Assays of biochemical parameters levels.....	34
2.10 Therapeutic effect of antagomir-148a delivered by (D-Asp ₈)-liposome on OVX mice	34
2.10.1 Experimental Design	34
2.10.2 Micro-CT analysis.....	36
2.10.3 Bone histomorphometric analysis	36
2.10.4 Assays of urine bone resorption marker levels.....	37
2.11 Statistical Analysis	37
3. Results.....	38
3.1 Preparation of (D-Asp ₈)-liposome-antagomir-148a	38
3.2 Characterization of (D-Asp ₈)-liposome-antagomir-148a	41
3.3 Tissue-selective delivery of antagomir-148a encapsulated by (D-Asp ₈)-liposome <i>in vivo</i>	43
3.4 Cell-selective delivery of antagomir-148a encapsulated by (D-Asp ₈)-liposome <i>in vivo</i>	46
3.5 Dose-response pattern and persistence of miR-148a knockdown by antagomir-148a delivered by (D-Asp ₈)-liposome <i>in vivo</i>	51
3.6 Cell-specific knockdown efficiency of miR-148a by antagomir-148a delivered by (D-Asp ₈)-liposome <i>in vivo</i>	54
3.7 Toxicity analysis in healthy mice after single/multiple dose(s) treatment.....	59
3.8 Therapeutic effects of antagomir-148a delivered by (D-Asp ₈)-liposome in OVX mice	61
4. Discussion	67
5. Conclusion.....	71
Reference	72
CURRICULUM VITAE	81